Latest news with #HealthCareSelectSectorSPDRFund
CNBC
15-05-2025
- Business
- CNBC
Healthcare shares are under pressure lately, but one stock is separating from the pack
Investors are generally avoiding the health care sector, and for good reason. While the Health Care Select Sector SPDR Fund (XLV) outperformed the S & P 500 and Nasdaq 100 through the end of April, May has meant disaster for pharmaceutical companies following the White House executive order on lowering drug prices. With the S & P 500 and Nasdaq 100 now trading back above their 200-day moving averages, and stocks like Eli Lilly & Co (LLY) and Johnson & Johnson (JNJ) feeling the pain of regulatory pressure, it's reasonable to expect very few opportunities in this former high-flying sector. However, a quick scan for stocks in the health care sector making new three-month highs yielded a number of promising charts showing improved technical characteristics. Separating from the pack? Let's review one of those names, HCA Healthcare (HCA) , and see how improved price momentum could lead to further gains. The daily chart of HCA shows how long it took for this health care provider to eclipse its 200-day moving average. After the first test in Q1, there were three additional failed attempts to push above this long-term trend barometer. Finally, at the end of April, HCA pushed above the 200-day and has now moved up to retest the price gap from October 2024. Note how the Relative Strength Index (RSI) stalled out around 60 during earlier attempts to push above the 200-day moving average. When HCA finally pushed above the 200-day, the RSI moved above the 60 level, showing positive momentum characteristics more common in bullish trends than bearish phases. The weekly chart suggests that this recent upside breakout was the result of a larger cyclical rotation from the pullback in late 2024 to a renewed uptrend phase: The weekly PPO, shown in the bottom panel, gave a buy signal in late February as HCA was nearing its 150-week moving average. We can see a similar pattern with the PPO indicator and moving average support in Q4 2024 and Q3 2022. In each instance, a pullback to the 150-week moving average was soon followed by a PPO buy signal to signal an "all clear" and a resumption of the primary uptrend. How can we manage risk as HCA retests the price gap from late 2024? Using the Ichimoku cloud model, we can see a dramatic break above cloud resistance in March, followed by a test of cloud support at the April low: There could be further pullbacks along the way, but as long as HCA remains above this cloud support zone, the primary trend appears bullish. - David Keller, CMT DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
21-03-2025
- Business
- Yahoo
IEFA Gains $929 Million as International Equity ETFs Lead
The iShares Core MSCI EAFE ETF (IEFA) pulled in $929.1 million Tuesday, bringing its total assets under management to $130.7 billion, according to daily fund flows data. The Vanguard S&P 500 ETF (VOO) attracted $1.6 billion, while the Health Care Select Sector SPDR Fund (XLV) gained $587.2 million. The iShares iBoxx $ High Yield Corporate Bond ETF (HYG) collected $520.3 million. On the outflows side, the SPDR S&P 500 ETF Trust (SPY) experienced the largest redemptions at $2.1 billion as markets resumed their selloff and the S&P 500 shed 1.1%. The iShares Core S&P 500 ETF (IVV) lost $1.3 billion, and the iShares U.S. Treasury Bond ETF (GOVT) also saw outflows of $1.3 billion ahead of the Federal Reserve rate announcement. International equity ETFs led asset classes with $1.6 billion in inflows, while leveraged funds gained $1.1 billion. U.S. equity ETFs saw outflows of $501.6 million. Overall, the ETF industry attracted $3.8 billion in total net inflows. Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change VOO Vanguard S&P 500 ETF 1,592.96 615,022.99 0.26% IEFA iShares Core MSCI EAFE ETF 929.12 130,695.76 0.71% XLV Health Care Select Sector SPDR Fund 587.21 38,837.62 1.51% HYG iShares iBoxx $ High Yield Corporate Bond ETF 520.26 15,410.72 3.38% IGV iShares Expanded Tech-Software Sector ETF 462.82 10,236.96 4.52% PTLC Pacer Trendpilot US Large Cap ETF 461.79 3,830.29 12.06% XLF Financial Select Sector SPDR Fund 446.50 51,155.42 0.87% QLD ProShares Ultra QQQ 401.15 6,469.68 6.20% USIG iShares Broad USD Investment Grade Corporate Bond ETF 398.43 12,858.78 3.10% TQQQ ProShares UltraPro QQQ 365.93 21,130.86 1.73% Ticker Name Net Flows ($, mm) AUM ($, mm) AUM % Change SPY SPDR S&P 500 ETF Trust -2,140.10 603,076.98 -0.35% IVV iShares Core S&P 500 ETF -1,329.75 543,586.09 -0.24% GOVT iShares U.S. Treasury Bond ETF -1,293.57 27,139.95 -4.77% QQQ Invesco QQQ Trust Series I -575.96 301,994.61 -0.19% XLP Consumer Staples Select Sector SPDR Fund -401.49 16,188.51 -2.48% VMBS Vanguard Mortgage-Backed Securities ETF -377.12 19,312.73 -1.95% EFAV iShares MSCI EAFE Min Vol Factor ETF -343.75 4,874.98 -7.05% AGG iShares Core U.S. Aggregate Bond ETF -314.52 124,529.38 -0.25% IWM iShares Russell 2000 ETF -243.65 65,379.80 -0.37% JNK SPDR Bloomberg High Yield Bond ETF -209.63 7,744.50 -2.71% Net Flows ($, mm) AUM ($, mm) % of AUM Alternatives -38.80 9,447.23 -0.41% Asset Allocation 67.07 23,253.39 0.29% Commodities ETFs 496.34 189,939.18 0.26% Currency 3.66 106,047.09 0.00% International Equity 1,633.05 1,672,131.90 0.10% International Fixed Income 452.75 279,014.73 0.16% Inverse 297.48 13,338.90 2.23% Leveraged 1,052.87 107,324.52 0.98% US Equity -501.56 6,493,926.55 -0.01% US Fixed Income 300.34 1,624,921.65 0.02% Total: 3,763.20 10,519,345.13 0.04% Disclaimer: All data as of 6 a.m. ET the date the article is published. Data are believed to be accurate; however, transient market data are often subject to subsequent revision and correction by the | © Copyright 2025 All rights reserved Sign in to access your portfolio
Globe and Mail
28-02-2025
- Business
- Globe and Mail
This Could Be the Best GLP-1 Stock to Buy in 2025
The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20% of their body weight, it creates considerable enthusiasm. And by sharing their results on social media, people are amping up that excitement to a whole new level. But to own a top drugmaker like Eli Lilly, which has an incredibly successful pair of GLP-1 drugs in Mounjaro and Zepbound, investors have to pay a significant premium -- 75 times its trailing earnings. That may be a bit steep given how competitive the GLP-1 market could become, as many healthcare companies are vying for a piece of that massive pie. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » If you're looking for a more reasonably priced investment, you may want to consider Amgen (NASDAQ: AMGN). Here's why I think it can be the best GLP-1 stock to buy this year. Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key consideration for patients, as they may need to stay on their medication for the long term. What's especially promising is that MariTide can help people lose up to 20% of their body weight after a year, per a recent phase 2 trial. While analysts were hoping to see weight loss of up to 25%, the company noted that there didn't appear to be a plateau, suggesting that greater weight loss may be achieved over a longer time frame. And in that study, many people took it less frequently than once a month, which may also have contributed to the slightly underwhelming trial results. But focusing just on weight loss numbers could be a mistake for investors. It's also important how well patients tolerate these drugs -- and by requiring fewer injections, MariTide could be a much easier weight loss treatment to maintain over the long haul. Despite the promising results, the stock remains cheap There's hope that MariTide could be the real deal, and take away market share from other GLP-1 drugs in the future. But investors don't appear to be pricing in that potential. Amgen's stock is trading at 41 times its trailing earnings and just 15 times its expected future earnings (based on analyst estimates). That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 times its future profits. In the past 12 months, Amgen's stock has risen by only 8%, as investors don't appear to be overly enthusiastic about its prospects, despite its potential in the GLP-1 drug market. Not only is it cheap, but it's also a fairly safe investment to hang on to now. Amgen has a diversified portfolio of drugs, several of which generated more than 30% revenue growth (year over year) in the fourth quarter of 2024. Last year, the company also generated $10.4 billion in free cash flow, which is sufficient to cover its dividend payments of $4.8 billion while leaving plenty of money to reinvest in its operations and pay down its debt. Amgen is a solid stock which could be due for a big rally When Amgen released its recent trial results for MariTide in November and they came in below analysts' expectations, the stock fell drastically. It was an overreaction in the market, and the stock has recovered since then. But its current valuation still doesn't appear to truly price in the potential for MariTide. While the drug isn't approved yet, if it does get the green light, this can be a much more valuable business in the years ahead. With its robust portfolio of treatments and strong financials, Amgen is one of the safer ways to invest in a company with a promising GLP-1 drug. Should you invest $1,000 in Amgen right now? Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,553!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Learn more » *Stock Advisor returns as of February 24, 2025
Yahoo
23-02-2025
- Business
- Yahoo
Stock Markets Analysis: Health Care Has Been a Top Sector
Late last year, I thought 2025 would be a year where some stocks (likely past laggards) would shine. So far, that's true. Market rotations are creating leaders out of past pained areas. For instance, health care stocks suffered in 2024. The S&P 500 health care sector, as represented by the exchange-traded fund Health Care Select Sector SPDR Fund (XLV), gained less than 3% last year, vastly underperforming the market. But so far, health care has been a top sector in 2025. And some small-cap health care names are being backed by powerful institutional buying. Recently, bullish sectors like technology and discretionary were negative for the year. But staples and health care, which were left for dead last year, showed 5.47% and 5.86% gains, respectively: We were on top of this in November, when MAPsignals data indicated a strong pattern emerging in the health care sector. On Nov. 15, 70 health care stocks were sold hard…too hard – they were oversold. When that happens, the sector tends to thrive afterwards. And history proves it. Well, history is repeating itself. Since that capitulation, XLV is up more than 6.5%. Notice how extreme outflows are typically great reversion signals: But MAPsignals data doesn't focus just on large-cap stocks alone. Our data covers stocks of all sizes. And remember how I said small-cap health care stocks have flourished? Well, MAPsignals data is signaling just how strong that Big Money support is right now, highlighting the most-bought equities. A big story in markets so far this year is small-cap health care stocks, though you may not hear that in the media too often. Not long ago, S&P SmallCap 600 sector returns showed just how dominant health care has been ruling the small-cap world, rising nearly 5%: When a sector is up that much, the specific stocks within it are booming. And that's been evident when you look at an ETF that captures the sector – the Invesco S&P SmallCap Health Care ETF (PSCH). As of this writing, it's up more than 8.3% year-to-date. Some of the top stocks held in PSCH are illuminating the MAPsignals data too. This is a great example of when having a market MAP comes in handy! When it comes to markets, 2025 is turning out to be a year of new leaders. That shouldn't be surprising because that's the nature of markets – they ebb and flow. Some of 2025's new leaders are emerging from the small-cap health care world. And they're shining brightly due to Big Money support. I said health care wouldn't be oversold for long, and it's true. History would suggest some of these smaller health care names will keep growing. But which ones? The ones being lifted by Big Money. And It always helps to use a MAP when trying to find the stocks with the most Big Money support. If you're a serious investor, Registered Investment Advisor (RIA), or a money manager looking for hedge-fund quality research, get started with a MAP PRO subscription today. This article was originally posted on FX Empire Big Money Flows to Visa Some Further Strength for the Dollar After Higher Inflation Meta Stock Rises with AI Future in Mind Live Nation Benefits from Strong Event Demand, Sponsorships Big Money Loves Fiserv Performance AI-Driven Advertising Has AppLovin Soaring
Yahoo
29-01-2025
- Health
- Yahoo
Merck & Co., Inc. (MRK): Is This Healthcare Stock A Good Buy?
We recently compiled a list of the . In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth potential, and ability to provide steady income through dividends. This sector encompasses pharmaceutical companies, healthcare providers, biotechnology firms, and medical device manufacturers, all of which are positioned to benefit from enduring trends like aging populations and advancements in medical technology. One of the most compelling reasons to include health stocks in a retirement portfolio is their defensive nature. Health care is a necessity, not a luxury, meaning demand for medical products and services remains steady, even during economic downturns. According to a report by Morningstar, the healthcare sector outperformed the broader market in 75% of US recessions over the past 50 years, demonstrating its ability to provide stability when other sectors falter. Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs. Global demographic trends also favor health stocks. The United Nations projects that the number of people aged 65 and older will double by 2050, reaching 1.5 billion. This aging population will drive increased demand for chronic disease management, prescription medications, and long-term care services. The US alone spends over $4.3 trillion annually on health care, according to the Centers for Medicare & Medicaid Services, accounting for nearly 20% of GDP. This figure is expected to rise to $6.8 trillion by 2030, driven by advances in medical technology and higher spending on aging-related health issues. Health stocks, particularly those of established pharmaceutical companies, often provide attractive dividend yields, making them ideal for income-focused retirees. Drug giants are known for consistently paying and increasing dividends. Dividends provide retirees with regular income, reducing the need to sell assets during market downturns. The healthcare sector is also at the forefront of technological innovation, offering exposure to high-growth areas such as biotechnology, precision medicine, and artificial intelligence in healthcare. Healthcare stocks provide diversification in a retirement portfolio as well, balancing out more volatile sectors like technology or energy. Additionally, healthcare ETFs like the Health Care Select Sector SPDR Fund offer exposure to a wide range of companies, spreading risk while capturing growth potential. For example, Health Care Select Sector SPDR Fund has delivered a 10-year annualized return of 13.4%, outperforming many other sectors. Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities. For this article, we selected health stocks that have solid businesses with recurring revenue streams, reliable dividend payouts, and burgeoning growth pipelines. These stocks are also popular among hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A close-up of a person's hand holding a bottle of pharmaceuticals. Number of Hedge Fund Holders: 86 Merck & Co., Inc. (NYSE:MRK) operates as a healthcare company worldwide. There are several aspects that make this company an attractive investment choice. Merck & Co. (NYSE:MRK) has achieved 14 consecutive years of dividend growth, surpassing the sector median of 2 years by 600%. Secondly, the company has also maintained 35 consecutive years of dividend payments, outperforming the sector median of 15 years by 133.33%. This shows the company's ability to generate profit and provide value to its shareholders, which are indicators of strong financial growth. Moreover, Merck & Co. (NYSE:MRK) has also announced a $17 million commitment over five years (2025-2030) to advance equitable access to culturally responsive care for people with heart conditions in the US communities. Overall MRK ranks 3rd on our list of the healthcare stocks to buy. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey.
